View Older Stories View More Recent Stories

Jun 9, 2022 08:00AM Horizon Therapeutics plc Named a Top Company for Executive Women
Jun 6, 2022 04:30PM Horizon Therapeutics plc to Present at the Goldman Sachs 43rd Annual Global Health Care Conference
Jun 2, 2022 08:00AM Horizon Therapeutics plc to Highlight Data and Education on Thyroid Eye Disease (TED) at the Endocrine Society (ENDO) 2022 Annual Conference
Jun 1, 2022 08:00AM Data Presented from the MIRROR Randomized Controlled Trial Demonstrate KRYSTEXXA® (pegloticase injection) Plus Methotrexate Resulted in Significant Improvement in Efficacy and Safety (Infusion Reacti
May 31, 2022 04:01PM Horizon Therapeutics plc Wins 2022 International CSR Excellence Award for #RAREis Adoption Fund
May 31, 2022 08:00AM Analysis from the Phase 3 N-MOmentum Study Demonstrates the Effectiveness of UPLIZNA® (inebilizumab-cdon) Among Neuromyelitis Optica Spectrum Disorder Patients with Genetic Variations
May 24, 2022 08:00AM Horizon Therapeutics plc to Present MIRROR Randomized Controlled Trial Primary Endpoint Data at The EULAR 2022 European Congress of Rheumatology
May 17, 2022 08:00AM Horizon Therapeutics plc Announces First Patient Enrolled in Phase 2 Trial Evaluating Daxdilimab (HZN-7734) for the Treatment of Alopecia Areata
May 16, 2022 09:00AM Horizon Therapeutics plc Ranked Second in Overall Corporate Reputation in U.S. PatientView Survey of Patient Groups
May 11, 2022 09:02AM Horizon Therapeutics plc Announces Dara Mann as a Healthcare Businesswomen’s Association 2022 Rising Star
May 11, 2022 08:30AM Horizon Therapeutics plc Launches Letter-Writing Campaign to Empower Those Living with Thyroid Eye Disease (TED) to Confront the Condition Head On
May 9, 2022 04:44PM Horizon Therapeutics and Chicago Sky Announce Multi-Year Partnership
May 4, 2022 07:00AM Horizon Therapeutics plc Reports First-Quarter 2022 Financial Results
May 3, 2022 09:15AM Horizon Therapeutics (HZNP) Announces Phase 2 Study of Dazodalibep (HZN-4920) Meets Primary Endpoint in Rheumatoid Arthritis
May 3, 2022 09:15AM Topline Data for Dazodalibep (HZN-4920) Meets Primary Endpoint in Rheumatoid Arthritis
May 2, 2022 04:05PM Horizon Therapeutics plc Launches #RAREis Global Advocate Grant Program to Support the Rare Disease Community
May 2, 2022 06:27AM Horizon Therapeutics (HZNP) Receives European Commission Approval of UPLIZNA for Treatment of Adults With Neuromyelitis Optica Spectrum Disorder
May 2, 2022 01:00AM Horizon Therapeutics plc Receives European Commission (EC) Approval of UPLIZNA® (inebilizumab) for the Treatment of Adults With Neuromyelitis Optica Spectrum Disorder (NMOSD)
Apr 27, 2022 08:01AM Horizon Therapeutics plc Among Top Companies for Overall Corporate Reputation in 2021 Global PatientView Survey of Patient Groups Worldwide
Apr 19, 2022 09:00AM Horizon Therapeutics and Massachusetts Institute of Technology (MIT) Solve Announce Second Annual Horizon Prize to Inspire Solutions that Improve the Quality of Life for the Global Rare Disease Commun
Apr 14, 2022 08:00AM Horizon Therapeutics plc to Release First-Quarter 2022 Financial Results and Host Webcast on May 4, 2022
Apr 11, 2022 09:20AM Horizon Therapeutics plc Named One of the Fortune 100 Best Companies to Work For®
Mar 31, 2022 08:30AM New Analysis Finds UPLIZNA® (inebilizumab-cdon) Effective for People with Newly-Presenting Neuromyelitis Optica Spectrum Disorder (NMOSD)
Mar 24, 2022 04:00AM Horizon Therapeutics plc Named as One of the Best Workplaces in Ireland
Mar 7, 2022 08:00AM Horizon Therapeutics plc Announces FDA Has Granted Priority Review of the Supplemental Biologics License Application (sBLA) for the Concomitant Use of KRYSTEXXA® (pegloticase injection) Plus Methotre
Mar 2, 2022 08:00AM Horizon Therapeutics plc Partners with Christine Ha, First Blind Contestant and Winner of MasterChef, to Amplify Her Unstoppable NMOSD Story
Mar 1, 2022 07:00AM Horizon Therapeutics plc Reports Fourth-Quarter 2021 and Full-Year 2021 Financial Results; Announces Full-Year 2022 Guidance
Feb 28, 2022 09:00AM Horizon Therapeutics plc Launches #RAREis Representation Program to Elevate Global Rare Disease Equity
Feb 23, 2022 08:00AM Horizon Therapeutics plc Initiates Phase 3 Clinical Trial (OPTIC-J) in Japan Evaluating Teprotumumab for the Treatment of Active Thyroid Eye Disease (TED)
Feb 21, 2022 04:05PM Horizon Therapeutics plc to Present at the Cowen and Company 42nd Annual Health Care Conference
Feb 16, 2022 08:15AM Horizon Therapeutics plc Names Sean Clayton Executive Vice President and General Counsel
Feb 16, 2022 08:00AM New Analysis Demonstrates UPLIZNA® (inebilizumab-cdon) Reduces Severity of Attacks Associated with Neuromyelitis Optica Spectrum Disorder (NMOSD)
Feb 15, 2022 11:02AM Horizon Therapeutics (HZNP) Announces New Post-Marketing Safety Analysis Shows Rate of Hearing-Related Events Associated with TEPEZZA Comparable with Clinical Trial Observations
Feb 15, 2022 11:00AM New Post-Marketing Safety Analysis Shows Rate of Hearing-Related Events Associated with TEPEZZA® (teprotumumab-trbw) Comparable with Clinical Trial Observations
Feb 15, 2022 09:00AM Horizon Therapeutics plc Partners with the Doug the Pug Foundation and Sing Me A Story Foundation to Bring Awareness to Rare Diseases Impacting Children through #RAREis Playlist
Feb 10, 2022 08:00AM Horizon Therapeutics plc Named Title Partner of the Irish Open
Feb 7, 2022 08:00AM Horizon Therapeutics plc to Release Fourth-Quarter and Full-Year 2021 Financial Results and Host Webcast on March 1, 2022
Jan 24, 2022 08:00AM Horizon Therapeutics plc Announces First Patient Enrolled in Phase 2b Pivotal Trial Evaluating HZN-825 for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
Jan 10, 2022 07:31AM Horizon Therapeutics (HZNP) Submits sNLA for Concomitant Use of KRYSTEXXA Plus Methotrexate for People Living with Uncontrolled Gout
Jan 10, 2022 07:30AM Horizon Therapeutics plc Submits Supplemental Biologics License for the Concomitant Use of KRYSTEXXA® (pegloticase injection) Plus Methotrexate for People Living with Uncontrolled Gout
Jan 6, 2022 08:00AM Horizon Therapeutics plc Announces Significant Expansion of East Coast Research and Development and Technical Operations Capability
Dec 23, 2021 08:00AM Horizon Therapeutics plc to Participate in Upcoming Investor Conferences
Dec 16, 2021 08:02AM Alpine Immune Sciences (ALPN) and Horizon Therapeutics (HZNP) Announce Exclusive License and Collaboration Agreement to Develop Novel Protein-Based Therapies for Autoimmune and Inflammatory Diseases
Dec 16, 2021 08:00AM Alpine Immune Sciences and Horizon Therapeutics plc Announce Exclusive License and Collaboration Agreement to Develop Novel Protein-Based Therapies for Autoimmune and Inflammatory Diseases
Dec 16, 2021 08:00AM Alpine Immune Sciences and Horizon Therapeutics plc Announce Exclusive License and Collaboration Agreement to Develop Novel Protein-Based Therapies for Autoimmune and Inflammatory Diseases
Dec 2, 2021 09:00AM Horizon Therapeutics plc Makes $100,000 Seed Donation to Support Fundraising Efforts to Renovate Emmett Till’s Home into a Museum and Theater
Dec 2, 2021 08:30AM Great Place to Work Names Horizon Therapeutics plc to Best Workplaces for Parents List
Dec 1, 2021 01:30AM Horizon Therapeutics plc Provides Academic Scholarships to Help Economically Disadvantaged Students in Ireland Further Their STEM Education
Nov 22, 2021 08:00AM New Analysis Published in Multiple Sclerosis and Related Disorders Supports the Efficacy of UPLIZNA® (inebilizumab-cdon) in Patients Previously Treated with Rituximab for Neuromyelitis Optica Spectru
Nov 15, 2021 09:00AM Horizon Therapeutics Recognizes Second Annual Thyroid Eye Disease (TED) Awareness Week with New Educational and Community Building Initiative
View More Recent Stories View Older Stories